Producer
Sterigenics (Sotera Health subsidiary)
Largest commercial EtO sterilization services company in the US (~50% market share); operates ~50 facilities globally including key US sites; faced multiple facility closures 2019-2022 due to EPA enforcement on EtO emissions, creating medical device supply chain crises.
2
Inputs supplied
3
Goods downstream
2
Facilities
0
Stories
What they make
2 inputs Sterigenics (Sotera Health subsidiary) supplies
Click an input to see every good that depends on it, every country that produces it, and every other company in the supply chain.
Where it shows up
Goods downstream
Essential goods that depend on something Sterigenics (Sotera Health subsidiary) makes, pick one to see the full supply chain.
Where they make it
2 facilities
Sterigenics Atlanta Georgia EtO Sterilization →
USGeorgia · processing
Sterigenics (Sotera Health) Atlanta area EtO sterilization facility; one of Sterigenics' largest US commercial sterilization sites serving medical device manufacturers; processes dialysis bloodlines, IV sets, catheters, and surgical supplies; subject to 2024 EPA NESHAP emission limits and subsequent regulatory uncertainty under Trump EPA 2025-2026 proposed rollback
Sterigenics Willowbrook Facility (now closed) →
USWillowbrook, Illinois · processing_plant
Closed September 2019 after Illinois EPA revoked operating permit due to EtO emissions linked to elevated cancer risk in surrounding community; processed ~3 Mt of medical devices/yr; closure forced hospitals to extend device shelf life waivers and import devices from international sterilization sites
What else they do
Business segments
The company's full revenue map, where this supply-chain role fits within their broader business.
Ethylene Oxide (EtO) Sterilization Services
60%Gamma Irradiation Services
25%E-Beam & X-Ray Sterilization
10%Consulting & Validation
5%
Intelligence
What's known
Sourced claims about this company's role in supply chains, chokepoints, concentration, incidents, dual-use connections.
Incident
The same molecule is also how roughly HALF of all sterile medical devices are sterilized — and that created a real crisis. When EtO-emission lawsuits and a cancer-cluster fight forced the closure of Sterigenics's Willowbrook, Illinois sterilization plant (2019), the FDA publicly warned of MEDICAL-DEVICE SHORTAGES, because few facilities are licensed to handle EO and many devices have no validated alternative sterilant. A carcinogenic gas no one wants in their neighborhood is simultaneously indispensable to the surgical supply chain. [verify: Willowbrook closed 2019, FDA warned of EtO sterilizer-closure device shortages; ~half devices EtO established]
U.S. FDA ↗Substitution2020
Sterigenics and its competitors are trying to replace EtO with X-ray and e-beam sterilization — but the capital cost is $50-100M per facility and most device manufacturers haven't revalidated their products for the alternative process FDA's EtO Sterilization Modernization Action Plan (2019-present) has pushed medical device OEMs to revalidate their products for gamma, X-ray, or e-beam sterilization. However, many devices were designed specifically for EtO (low-temperature cycles, deep penetration through complex geometries) and cannot be irradiated without material or sterility performance changes. Revalidation under ISO 11135 requires new biological indicator studies and FDA regulatory submissions; the process takes 2-5 years per device family. Sterigenics itself has invested in X-ray facilities, but only ~25% of EtO-sterilized device volume has plausible near-term substitution paths. The rest remains structurally dependent on EtO indefinitely.
US Food and Drug Administration ↗Origin2023
Sterigenics traces its origin to the early application of gamma radiation for industrial sterilization in the 1950s, when nuclear research programs produced cobalt-60 as a byproduct and commercial applications were explored. The company was known as Radiation Services Company and later operated under various names through a series of private equity ownership changes before being consolidated into Sotera Health (which went public on Nasdaq in 2020). Its dominance in EtO sterilization grew because EtO penetrates complex device geometries that gamma radiation cannot reach safely, making it the only viable option for certain catheters, sutures, and coated implants. By 2019, Sterigenics had built a near-monopoly on EtO sterilization services -- until the EPA and state attorneys general began closing facilities over carcinogenic ethylene oxide emissions, creating the first major US medical device supply chain crisis driven by environmental enforcement rather than demand or production failures.
Sterigenics (Sotera Health) ↗